The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Alkem’s domestic business grew 9.7 per cent versus the Indian pharmaceutical market growth of 8.5 per cent
The new facility will enhance AbbVie’s chemical synthesis capacity to support domestic production of current and next-generation neuroscience, immunology, and oncology medicines
Athena is also exploring the use of this technology for expanded carrier screening
Vasograin Plus represents a major advancement in the treatment of migraine
The company’s largest center for medical device applications, serving the entire Asian market
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich
ART-123 is a recombinant human thrombomodulin approved in Japan in 2008
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Subscribe To Our Newsletter & Stay Updated
